微创医疗(00853.HK)由上市高位吐逾8% 拟溢价发CB及传旗下微创医疗机器人拟来港上市
微创医疗(00853.HK)拟溢价发7亿美元五年期零息CB及传旗下微创医疗机器人拟来港上市。该股四连升兼连续两天创上市新高後,投资者藉消息先行获利回吐,股价曾回吐至64.15元,现造64.4元,回吐8.1%,成交增至1,835万股,涉资12.04亿元。
微创公布,建议发行本金额7亿美元五年期零息可换股债券(CB),初步换股价每股92.8163元(较昨天收市价有溢价32.5%),若CB获悉数转换,涉及5,851.97万股或占公司扩大後股本3.12%。预计所得款项净额约6.9亿美元,将用作研发投资、若干资本开支及营运资金用途。
另外,据路透旗下IFR引述消息指,微创医疗旗下持股53.75%微创医疗机器人股份正计划年内来港上市,集资约7-10亿美元,正与中金和摩根大通合作筹备上市相关工作。另有消息指,微创机器人最快本月正式提交上市申请。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.